Neurosense Therapeutics Ltd(NRSN)

0.8065+0.0178+2.26%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement
  Reuters · 03-19 03:36
  NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement
- NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement
  Reuters · 03-19 03:36
  NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement
- NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement
  Reuters · 03-19 03:36
  NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement
- NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference
  Reuters · 03-18 20:04
  NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference
- Health Rounds: Blood test improves detection of endometriosis
  Reuters · 03-18 03:31
  Health Rounds: Blood test improves detection of endometriosis
- Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)
  TIPRANKS · 03-17
  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)
- NeuroSense Phase 2b PARADIGM trial links PrimeC to 36% slower ALS progression and 64% lower complication risk
  Reuters · 03-16
  NeuroSense Phase 2b PARADIGM trial links PrimeC to 36% slower ALS progression and 64% lower complication risk
- Jama Neurology Publishes Results From Paradigm Phase 2B Trial of Primec in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
  THOMSON REUTERS · 03-16
  Jama Neurology Publishes Results From Paradigm Phase 2B Trial of Primec in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- NeuroSense Therapeutics shareholders approve articles amendment to increase registered share capital
  Reuters · 03-11
  NeuroSense Therapeutics shareholders approve articles amendment to increase registered share capital
- Roth Capital Partners Initiates Neurosense Therapeutics at Buy
  MT Newswires Live · 03-10
  Roth Capital Partners Initiates Neurosense Therapeutics at Buy
- NeuroSense initiated with a Buy at Roth Capital
  TIPRANKS · 03-10
  NeuroSense initiated with a Buy at Roth Capital
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)
  TIPRANKS · 03-10
  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)
- NeuroSense reports additional long-term survival data from PARADIGM 2b trial
  TIPRANKS · 02-18
  NeuroSense reports additional long-term survival data from PARADIGM 2b trial
- NeuroSense reports PrimeC cut ALS death risk 65% in Phase 2b trial
  Reuters · 02-18
  NeuroSense reports PrimeC cut ALS death risk 65% in Phase 2b trial
- NeuroSense Therapeutics Proposes Increase in Registered Share Capital at Upcoming Shareholder Meeting
  Reuters · 02-14
  NeuroSense Therapeutics Proposes Increase in Registered Share Capital at Upcoming Shareholder Meeting
- NeuroSense erhält australisches Patent für PrimeC-Kombinationstherapie
  Reuters · 02-09
  NeuroSense erhält australisches Patent für PrimeC-Kombinationstherapie
- NeuroSense files $150M mixed securities shelf
  TIPRANKS · 01-30
  NeuroSense files $150M mixed securities shelf
- Neurosense Therapeutics Ltd : Files for Mixed Shelf Offering of up to $150 Mln - SEC Filing
  THOMSON REUTERS · 01-30
  Neurosense Therapeutics Ltd : Files for Mixed Shelf Offering of up to $150 Mln - SEC Filing
- NeuroSense Therapeutics Granted U.S. Patent for Alzheimer's Disease Treatment, Extending Protection Through 2043
  Reuters · 01-21
  NeuroSense Therapeutics Granted U.S. Patent for Alzheimer's Disease Treatment, Extending Protection Through 2043
- Press Release: World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
  Dow Jones · 01-08
  Press Release: World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Company Profile
Company Name
Neurosense Therapeutics Ltd
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.neurosense-tx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- 2025-08-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-07
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-01-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-06
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-09
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-19
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-05-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-05-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-10
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-04-04
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-12-04
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence

1D
5D
Day
Week
Month

Loading ...

High

0.8150

Open

0.7800

Volume%

0.16

Low

0.7775

0.7887

T/O Rate

0.14%

To The Moon

Neurosense Therapeutics Ltd(NRSN)

Company Profile

Most Discussed